Browsing by Author "Rodriguez-Morera, Jaime"

Sort by: Order: Results:

  • Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study
    Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Díez Pérez, Adolfo; Rial, Abora; Cos, Maria Lourdes; Campodarve, Isabel; Rodriguez-Morera, Jaime; Garcia Giralt, Natàlia; Nogués Solan, Francesc Xavier (Springer, 2019)
    PURPOSE: The most frequent adverse effects of aromatase inhibitors (AI) are arthralgia and bone loss induction. These reduce the quality of life of patients and their adherence to the treatment. This study evaluates the ...
  • Bone health evaluation one year after aromatase inhibitors completion
    Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Casamayor, Guillem; Cos, Maria Lourdes; Rial, Abora; Rodriguez-Morera, Jaime; Tusquets Trias de Bes, Ignacio; Díez Pérez, Adolfo; Garcia Giralt, Natàlia; Nogués Solan, Francesc Xavier (Elsevier, 2018)
    Breast cancer patients treated with aromatase inhibitors (AIs) experience increased bone loss during their treatment. However, there is little information about bone mineral density (BMD) after completing AI-treatment. The ...
  • Calcifediol treatment and COVID-19-related outcomes
    Nogués Solan, Francesc Xavier; Ovejero Crespo, Diana; Pineda-Moncusí, Marta; Bouillon, Roger; Arenas Jiménez, María Dolores; Pascual Santos, Julio; Ribes, Anna; Guerri-Fernandez, Robert; Villar García, Judit; Rial, Abora; Gimenez-Argente, Carme; Cos, Maria Lourdes; Rodriguez-Morera, Jaime; Campodarve, Isabel; Quesada-Gómez, J.M.; García-Giralt, Natalia (Oxford University Press, 2021)
    Context: COVID-19 is a major health problem because of saturation of intensive care units (ICU) and mortality. Vitamin D has emerged as a potential treatment able to reduce the disease severity. Objective: This work aims ...
  • TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
    Rodríguez Sanz, Maria, 1984-; Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Garcia Giralt, Natàlia; Martos, Tamara; Tusquets Trias de Bes, Ignacio; Martínez-García, Maria; Rodriguez-Morera, Jaime; Díez Pérez, Adolfo; Albanell Mestres, Joan; Nogués Solan, Francesc Xavier (Elsevier, 2016)
    INTRODUCTION: Patients with breast cancer under aromatase inhibitor (AI) treatment often develop osteoporosis and their average bone loss rate is twice that of natural reduction during menopause, increasing fracture risk. ...